Opinion|Videos|April 3, 2025

Checkpoint Inhibitors for Treatment of NMIBC

Experts share their initial impressions of the available data on immunotherapies, including PD-L1 inhibitors durvalumab and sasanlimab, being evaluated in bacille Calmette-Guérin (BCG)–unresponsive patients with non–muscle-invasive bladder cancer (NMIBC).

Episodes in this series

Video content above is prompted by the following:

  • In addition to recent approval, several immunotherapies such as PD-(L)-1 inhibitors (durvalumab and sasanlimab) are being evaluated in BCG-unresponsive patients. What are your initial impressions of available data with immunotherapies?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!

Related Content

Latest CME

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment
Virtual Event

Breakthroughs in Non–Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

February 23, 2026

View more
Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD
Video

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

View more